Kodiak Sciences (NASDAQ:KOD) Earns Neutral Rating from HC Wainwright

Kodiak Sciences (NASDAQ:KOD)‘s stock had its “neutral” rating reiterated by analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $3.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 17.19% from the stock’s previous close.

Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, December 9th.

Kodiak Sciences Stock Down 8.9 %

KOD opened at $2.56 on Monday. Kodiak Sciences has a 52 week low of $2.19 and a 52 week high of $11.60. The stock has a market cap of $134.72 million, a PE ratio of -0.70 and a beta of 2.26. The business has a 50 day moving average of $4.66 and a 200-day moving average of $5.45.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.06. Equities analysts anticipate that Kodiak Sciences will post -3.45 EPS for the current year.

Institutional Investors Weigh In On Kodiak Sciences

Several hedge funds have recently added to or reduced their stakes in the stock. FMR LLC raised its position in shares of Kodiak Sciences by 26.4% in the 3rd quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after purchasing an additional 41,987 shares during the last quarter. State Street Corp increased its stake in Kodiak Sciences by 1.8% during the 3rd quarter. State Street Corp now owns 816,634 shares of the company’s stock valued at $2,131,000 after purchasing an additional 14,711 shares in the last quarter. Barclays PLC raised its holdings in Kodiak Sciences by 65.5% in the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock worth $208,000 after buying an additional 31,527 shares during the last quarter. Geode Capital Management LLC raised its holdings in Kodiak Sciences by 1.7% in the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock worth $2,007,000 after buying an additional 12,783 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Kodiak Sciences by 220.9% in the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock worth $117,000 after buying an additional 30,735 shares in the last quarter. 89.06% of the stock is owned by institutional investors.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.